Clinical Trials Browser

Phase 2 × elotuzumab × Myeloid × Clear all

NCT04517851 2026-01-13

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Phase 2 Active not recruiting

Polycythemia Vera, Primary Myelofibrosis